MC 510050
Alternative Names: MF-EA-371 deltaLatest Information Update: 05 Oct 2004
At a glance
- Originator Daiichi Pharmaceutical; Essential Therapeutics [CEASED]
- Developer Essential Therapeutics [CEASED]
- Class Antibacterials
- Mechanism of Action Membrane protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pseudomonal infections
Most Recent Events
- 05 Oct 2004 Discontinued - Preclinical for Pseudomonal infections in USA (unspecified route)
- 06 May 2003 No development reported - Preclinical for Pseudomonal infections in USA (unspecified route)
- 26 Sep 2000 Preclinical development for Pseudomonal infections in USA (Unknown route)